| Merck scraps another late-stage Alzheimer's drug study | | | NEW YORK (Reuters) - Merck & Co Inc on Tuesday said it will end another late-stage trial of an Alzheimer's drug because it was unlikely to work, adding to the pile-up of failures to find an effective treatment for the mind-wasting disease. |
| |
| Novartis gains U.S. approval for delayed MS drug | | | ZURICH (Reuters) - Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. |
| |
| Amerisource deal may not keep Walgreens competitive: analysts | | | (Reuters) - Walgreens' potential deal for drug distributor AmerisourceBergen will boost its cash flow and push it deeper into a lucrative specialty pharmacy market, but may fail to keep it competitive in an evolving U.S. healthcare sector, analysts said. |
| |
| | |
